For Immediate Release
Chicago, IL – October 1, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Medtronic plc (
MDT Quick Quote MDT - Free Report) , Boston Scientific Corporation ( BSX Quick Quote BSX - Free Report) , Catalent, Inc. ( CTLT Quick Quote CTLT - Free Report) , Baxter International Inc. ( BAX Quick Quote BAX - Free Report) and Hill-Rom Holdings, Inc. ( HRC Quick Quote HRC - Free Report) . Here are highlights from Thursday’s Analyst Blog: MedTech Thrives on M&A Frenzy: 3 Stocks to Focus On
After a tumultuous 2020, the U.S. MedTech sector is gradually on the recovery path with the opening up of the economy and easing of restrictions. Overall, the sector suffered huge setbacks last year due to the economic standstill, whereas the companies depending on elective procedures were hurt even more.
To withstand the continued pandemic-led impacts, several MedTech players are currently in the mode of altering their business models. Further, with the rising concerns of new infections due to the emergence of new SARS-CoV-2 variants, companies are increasingly consolidating their positions in the global markets via strategic buyouts. Accordingly, merger and acquisition (M&A) activities, which had taken a back seat amid the pandemic-led market volatility, are gradually picking up.
With key MedTech companies actively participating in buyouts over the past few months to drive growth, it might be prudent for investors to take a look at such stocks.
MedTech M&As in 2021: A Snapshot
Market watchers are quite upbeat about the recent flurry of acquisitions by various MedTech players.
Per an article on Evaluate, deals worth $31.5 billion were closed in the first six months of 2021, surpassing the total worth of deals closed in 2020. Pent-up deals of 2020, kept on hold due to the pandemic, are expected to be the primary driving force.
The innovators that become the standard acquisition targets for MedTech’s more prominent players depend on continued funding to support their research and development activities, especially in the form of venture capital (VC). The sector attracted around $9.1 billion in VC in the 12-month period ended June 2021, reflecting an uptick of 34% over the previous period (
Going by EY’s Pulse of the industry 2021 report).
Interestingly, the global VC investment market was worth $197.7 billion in 2020 and is expected to see a CAGR of around 16% between 2021 and 2026 (
per Research and Markets). Factors like expanding investment activities in diverse industry verticals in MedTech and increasing investments from mutual funds and banking institutions in VC are likely to drive the market. Given the expected free flow of funds, a further slew of buyouts is expected to conclude over the year's second half.
Within MedTech, stalwarts like
Medtronic deserve mention. The well-known medical technology player entered into a definitive agreement with Intersect ENT in August. The takeover is expected to expand Medtronic’s portfolio of products used during ear, nose and throat procedures. 3 Hot M&As in Second-Half 2021
Here we have listed three stocks from the MedTech space that have recently announced M&A activities and might turn out to be prudent investment choices given their long-term growth potential.
Boston Scientific Corp. is the first stock that investors can look at. This month, this Zacks Rank #3 (Hold) company announced an agreement to acquire Devoro Medical, Inc. The buyout is expected to aid Boston Scientific in utilizing the former’s WOLF Thrombectomy Platform to complement and expand its offerings to a full suite of interventional strategies for thromboemboli, which also includes the following: EkoSonic Endovascular System and the AngioJet Thrombectomy System. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its long-term expected earnings growth rate is pegged at 9.3%. The company is expected to report full-year 2021 revenue growth of 21.2%. Year to date, the stock has gained 22.1% compared with the
industry’s 1.6% rise. Since the announcement of the acquisition, shares of the company have rallied 1.2%.
Renowned global provider of advanced delivery technologies,
Catalent, is the next stock on our list. In August, this Zacks Rank #3 company reached an agreement to acquire Bettera Holdings, LLC. The buyout is expected to complement and accelerate Catalent’s global softgel and oral dose formulation and manufacturing business.
Its long-term expected earnings growth rate is pegged at 19.7%. The company is expected to report full-year fiscal 2022 revenue growth of 13.4%. Year to date, the stock has gained 28.9% against the
industry’s 15.1% fall. Since the announcement of the acquisition, shares of the company have gained 3%.
Key global provider of medical products,
Baxter International, is the final stock on our list. The Zacks Rank #3 company, this month, inked a definitive agreement under which it will acquire Hill-Rom Holdings. The transaction is likely to enable Baxter to provide a broader range of medical products and services to patients and clinicians across the care continuum on a global scale.
Its long-term expected earnings growth rate is pegged at 10%. The company is expected to report full-year 2021 revenue growth of 8%. Year to date, the stock has gained 1.9% against the
sector’s 6.7% fall. Since the announcement of the acquisition, shares of the company have gained 0.9%.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.